Bayer Aktiengesellschaft

Bayer Healthcare Aktiengesellschaft

Farbenfabriken Bayer Aktiengesellschaft

Beiersdorf Ag

Bayer Schering Pharma Ag

Bayer Aktiengellschaft

Delf Schmidt

Hilmar Bischoff

Rolf Angerbauer

Peter Fey

Walter Hubsch

Dieter Petzinna

Thomas Philipps

Gunter Schmidt

Arndt Brandes

Gunter Thomas

Carsten Schmeck

Werner Frommer

Klaus-Dieter Bremm

Walter Puls

Karl G Metzger

Beatrix Stelte-Ludwig

Gunter Benz

Jorg Pfitzner

Ulf Brueggemeier

Martin Bechem

Joachim Schuhmacher

Matthias Muller-Gliemann

Christoph Gerdes

Elke Stahl

Klaus Urbahns

Hans-Peter Krause

J&uuml;rgen Stoltefuss

Wolfgang Paffhausen

Andreas Schade

Theo Schroder

Michael L&ouml;gers

Dietmar Schafer

Paul Naab

J&ouml;rg Keldenich

Hans-Joachim Zeiler

Klemens Lustig

Andrea Vaupel

Holger Paulsen

Markus Albers

Jürgen Stoltefuss

Horst Weyland

Thoams Krahn

Stefan Wohlfeil

Bodo Junge

Jurgen Stoltefuss

Jörg Keldenich

Martin Scheer

Joerg Keldenich

Thomas Krahn

Andreas Schoop

Lutz Muller

Michael Lögers

Henry Giera

Christiane Faeste

Michael Conrad

Joachim Bender

Michael H&auml;rter

Wilfried Kaufmann

Klaus Bauer

Jorg Petersen Von Gehr

Gerhard Mueller

Robert R Schmidt

Andreas Knorr

Rudolf Schohe-Loop

Dieter Berg

Thomas Lampe

Horst Boshagen

Josef Pernerstorfer

Bernd Riedl

Axel Kretschmer

Helmut Haning

Stefan Antons

Claudia Hirth-Dietrich

Michael Härter

Franz-Josef Van Der Staay

Jorg Baumgarten

Martin Radtke

Walter H&uuml;bsch

Chantal F&uuml;rstner

Hans P Krause

Erich Rauenbusch

Friedrich Schmidt

Verena Vöhringer

Heiner Apeler

Stephan Lensky

Wolfgang Kanhai

Wolfgang Karl

Werner Schr&ouml;der

Elmar Reinhold Burchardt

Ulrich Müller

Gu/ Nter Thomas

Peter Reinemer

Uwe Keup

Stephan Nicholas M&uuml;ller

Frank B&ouml;ss

Ulf Br&uuml;ggemeier

Jens Erg&uuml;den

Bernhard Schmidt

J&ouml;rg Petersen Von Gehr

Matthias M&uuml;ller-Gliemann

A process for the quantitative optical analysis of fluorescently labeled biological cells involves contacting a cell layer on a transparent support at the bottom of a reaction vessel with a solution containing the fluorescent dye. This process can also be used for improving the sensitivity in the quantitative optical analysis of a luminescent biological cell layer. Analogously, these process principles can also be used in receptor studies for the masking of the interfering background radiation in the quantitative optical analysis of fluorescently or luminescently labelled reaction components. In this case, a receptor layer at the bottom of a reaction vessel is in contact with a solution in which a fluorescent or luminescent ligand is dissolved.

Masking of the background fluorescence and luminescence in the optical analysis of biomedical assays

In a process for the quantitative optical analysis of fluorescently labelled biological cells, a cell layer on a transparent support at the bottomof a reaction vesselis in contact with a solutioncontaining the fluorescent dye. The sensitivity of analytical detection can be considerably improved if to the fluorescent dyealready present in addition a masking dye, which absorbs the excitation lightfor the fluorescent dyeand/or its emission light, is added to the solutionand/or if a separating layerpermeable to the solution and absorbing and/or reflecting the excitation lightor the emission lightis applied to the cell layer at the bottom. This process can also be used for improving the sensitivity in the quantitative optical analysis of a luminescent biological cell layer. The separating layermust in this case be composed such that it has a high power of reflection for the luminescent light. Analogously, these process principles can also be used in receptor studies for the masking of the interfering background radiation in the quantitative optical analysis of fluorescently or luminescently labelled reaction components. In this case, a receptor layerat the bottomof a reaction vesselis in contact with a solution (supernatant) in which a fluorescent or luminescent ligandis dissolved. The sensitivity and accuracy of the analytical detection can be considerably improved here if a masking dyewhich absorbs the excitation lightfor the fluorescent dye and/or its emission light or (in the case of luminescent ligands) the luminescent light is added to the supernatant. Instead of the masking dye in the solutionor optionally as an additional measure, a separating layerpermeable to the solutionand absorbing and/or reflecting the excitation lightand/or the emission light or the luminescent light can be applied to the cell or receptor layerat the bottom

Masking background fluorescence and luminescence in the optical analysis of biomedical assays

The invention relates to substituted 2-Phenyl-3(2H)-Pyridazinones, to a method for the production thereof, and to their use as medicaments for the prophylaxis and/or treatment of diseases in humans and/or animals.

Substituted 2-phenyl-3(2h)-pyridazinones

Hetero-tetrahydroquinolines can be prepared either by condensing correspondingly substituted hetero-tetrahydroquinoline aldehydes with the desired substituent or by reducing the corresponding keto-substituted hetero-tetrahydroquinolines, followed by introduction of the desired substituent by customary methods. The hetero-tetrahydroquinolines are suitable for use as active compounds in medicaments, in particular in medicaments for treating artheriosclerosis and dyslipidaemias.

4-Heteroaryl-tetrahydroquinolines and their use as inhibitors of the cholesterin-ester transfer protein

In a process for the quantitative optical analysis of biological cells labelled with a fluorescent dye, the sensitivity of analytical detection can be considerably improved if a masking dye, which absorbs the excitation light for the fluorescent dye and/or its emission light is added to the solution surrounding the biological cells and/or if a separating layer permeable to the solution and absorbing and/or reflecting the excitation light or the emission light is applied to a layer of the biological cells at the bottom of a reaction vessel. This process can also be used for improving the sensitivity in the quantitative optical analysis of a luminescent biological cell layer. Analogously, these process principles can also be used in receptor studies for the masking of the interfering background radiation in the quantitative optical analysis of fluorescently or luminescently labelled reaction components.

The present invention relates to biphenyl and biphenyl-analogous compounds, their preparation and use as pharmaceutical compositions, as integrin antagonists and in particular for the production of pharmaceutical compositions for the treatment and prophylaxis of cancer, arteriosclerosis, restenosis, osteolytic disorders such as osteoporosis and ophthalmic diseases. The compounds according to the invention have the formula (1) wherein

Biphenyl and biphenyl-analogous compounds as integrin antagonists

In a process for the quantitative optical analysis of fluorescently labelled biological cellsa cell layer on a transparent support at the bottomof a reaction vesselis in contact with a solutioncontaining the fluorescent dyeThe sensitivity of analytical detection can be considerably improved if to the fluorescent dyealready present in addition a masking dyewhich absorbs the excitation lightfor the fluorescent dyeand/or its emission lightis added to the solutionand/or if a separating layerpermeable to the solution and absorbing and/or reflecting the excitation lightor the emission lightis applied to the cell layer at the bottomThis process can also be used for improving the sensitivity in the quantitative optical analysis of a luminescent biological cell layer. The separating layermust in this case be composed such that it has a high power of reflection for the luminescent light. Analogously, these process principles can also be used in receptor studies for the masking of the interfering background radiation in the quantitative optical analysis of fluorescently or luminescently labelled reaction components. In this case, a receptor layerat the bottomof a reaction vesselis in contact with a solution (supernatant) in which a fluorescent or luminescent ligandis dissolved. The sensitivity and accuracy of the analytical detection can be considerably improved here if a masking dyewhich absorbs the excitation lightfor the fluorescent dye and/or its emission light or (in the case of luminescent ligands) the luminescent light is added to the supernatantInstead of the masking dye in the solutionor optionally as an additional measure, a separating layerpermeable to the solutionand absorbing and/or reflecting the excitation lightand/or the emission light or the luminescent light can be applied to the cell or receptor layerat the bottom

Masking background flourescence and luminescence in optical analysis of biomedical assays

The invention relates to novel benzofuran derivatives, to processes for preparing them and to their uses in medicaments.

Benzofuran derivatives

4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the cholesterin-ester transfer protein

The tetrahydroquinolines can be prepared by condensing appropriately substituted tetrahydroquinoline aldehydes with suitable substances and subsequently varying the substituents present by customary methods. The tetrahydroquinolines are suitable as active compounds in medicaments, in particular in medicaments for the treatment of arteriosclerosis and dyslipidaemias.

4-Phenyltetrahydrochinoline utilized as an inhibitor of the cholesterol ester transfer protein

&bgr;-phenylalanine derivatives as integrin antagonists

Substituted tetrahydro-naphthalenes and analogous compounds are prepared by reducing or condensing appropriate functional substituents in substituted tetrahydro-naphthalenes and analogous compounds by customary methods and converting functional groups in this manner into the desired groups. The compounds according to the invention are suitable for use as active compounds in pharmaceuticals, in particular in pharmaceuticals for treating arteriosclerosis and also dyslipidaemias.

Substituted tetrahydronaphthaline and analogous compounds

The tetrahydroquinolines can be prepared by condensing appropriately substituted tetrahydroquinoline aldehydes with suitable substances and subsequently varying the substituents present by customary methods. The tetrahydroquinolines are suitable as active compounds in medicaments, in particular in medicaments. for the treatment of arteriosclerosis and dyslipidaemias.

4-phenyltetrahydrochinoline utilized as an inhibitor of the cholesterol ester transfer protein

The present invention relates to compounds of general formula (I) and their preparation and use for the production of pharmaceuticals, and pharmaceuticals comprising these compounds.

1,4-benzodiazepinone derivatives and their use as integrin antagonists

Growing community of inventors

Wuppertal, Germany

Delf Schmidt